Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)

Authors

  • Jennifer Sims-Mourtada
  • Serguei Casteneda
  • David Huang
  • John McGlade
  • Sunjay Shah
  • Lindsay Romak
  • Adam Raben

Keywords:

Stereotactic body radiotherapy (SBRT), Dosimetric, Immunotherapy, Radiation

Abstract

Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies
such as pembrolizumab. Radiation has been shown to activate the immune system, and in combination with immunotherapy may
lead to systemic anti-tumor responses. However, the exact dose regimens needed to induce synergistic responses are unclear. Here,
we report a dosimetric characterization of a patient treated with stereotactic radiation in combination with immune check-point
therapy.

Downloads

Published

2018-01-31

How to Cite

Jennifer Sims-Mourtada, Serguei Casteneda, David Huang, John McGlade, Sunjay Shah, Lindsay Romak, & Adam Raben. (2018). Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT). Cancer Studies and Molecular Medicine , 4(1), 1–4. Retrieved from https://openventio.us/index.php/CSMM/article/view/1452

Issue

Vol. 4 No. 1 (2018): Volume 4 Issue 1 2018

Section

Articles

License

All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Most read articles by the same author(s)